Acurx Pharmaceuticals: Progress and Financial Results for Q2 2026#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Acurx Pharmaceuticals: Progress and Financial Results for Q2 2026
Acurx Pharmaceuticals, Inc. reports significant advancements in developing new antibiotics and provides its financial performance for Q2 2026.
third-news.com
August 14, 2026 at 11:08 AM
Acurx Pharmaceuticals: Progress and Financial Results for Q2 2026#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program
Acurx Pharmaceuticals has unveiled a new clinical trial program for Ibezapolstat targeting recurrent CDI, aiming to transform treatment standards and efficacy.
third-news.com
March 9, 2026 at 12:14 PM
Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment